Trends in Molecular Medicine
@TrendsMolecMed
Followers
6K
Following
1K
Media
649
Statuses
5K
Reviews journal by Cell Press publishing all aspects of human diseases, diagnostics, therapeutics, and disease prevention. Tweets by editor Dr. Aliki Perdikari.
London, UK
Joined April 2011
The July issue of @TrendsMolecMed is now online!. Special thanks to all the authors and reviewers for their contribution!. I am happy to receive your feedback and ideas for topics so please get in touch!
0
0
4
RT @TrendsMolecMed: ONLINE NOW: Prostate cancer germline variants with therapeutic implications .
0
3
0
ONLINE NOW: Prostate cancer germline variants with therapeutic implications
0
3
5
ONLINE NOW: Autoantibodies as drivers of neuropathic pain
0
1
0
RT @TrendsMolecMed: ONLINE NOW: From pathophysiology to treatment in transthyretin cardiac amyloidosis https://t.c….
0
2
0
ONLINE NOW: From pathophysiology to treatment in transthyretin cardiac amyloidosis
0
2
1
RT @TrendsMolecMed: ONLINE NOW: Spinocerebellar ataxia type 3: from pathogenesis to promising therapeutics https:/….
0
1
0
ONLINE NOW: Host–microbe interactions in NAD+ metabolism
0
3
1
ONLINE NOW: Spinocerebellar ataxia type 3: from pathogenesis to promising therapeutics
0
1
0
RT @sandaklyj: Happy to share our latest from the lab. In this brief review, we provide a visually engaging overview of Rett Syndrome and t….
0
3
0
RT @TrendsMolecMed: ONLINE NOW: Rett syndrome: a complex disorder with promising therapeutic prospects https://t.c….
0
2
0
ONLINE NOW: Rett syndrome: a complex disorder with promising therapeutic prospects
0
2
4
RT @TrendsMolecMed: ONLINE NOW: RNA immunotherapy: revolutionizing cancer and autoimmune disease treatments https:….
0
1
0
ONLINE NOW: RNA immunotherapy: revolutionizing cancer and autoimmune disease treatments
0
1
4
ONLINE NOW: ILC2s in cancer: good, bad, or stay tuned?
0
1
1
RT @TrendsMolecMed: ONLINE NOW: The endoplasmic reticulum proteostasis network and bone disease .
0
1
0
RT @TrendsMolecMed: ONLINE NOW: Next-generation immune profiling – beyond blood cancer cells .
0
2
0
